Ticker: MNPR

Snapshot - Monopar Therapeutics Inc (NASDAQ: MNPR) Clinical-stage biopharma advancing ALXN1840 (Wilson disease) and MNPR‑101 radiopharmaceuticals; filing an NDA planned for early 2026 and continuing Phase 1 radiopharma trials while managing cash runway into late 2026. Key facts & figures (straigh...

Monopar Therapeutics Inc. (NASDAQ: MNPR) has recently released its financial results for the first quarter ended March 31, 2025. Below is an overview of the company's financial performance and key points from the income statement. Financial Highlights Net Loss: The company's net loss was $2.625 ...